Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Current Deferred Revenue for 6 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue fell 70.6% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 70.6% year-over-year, with the annual reading at $1.9 million for FY2025, 70.6% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.9 million at Caribou Biosciences, down from $4.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $31.1 million in Q2 2023, with the low at $50000.0 in Q2 2021.
  • Average Current Deferred Revenue over 5 years is $9.4 million, with a median of $6.4 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue skyrocketed 25184.0% in 2022, then tumbled 90.91% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $8.7 million in 2021, then skyrocketed by 197.5% to $25.9 million in 2022, then tumbled by 89.0% to $2.8 million in 2023, then skyrocketed by 126.41% to $6.4 million in 2024, then plummeted by 70.6% to $1.9 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $1.9 million, $4.0 million, and $4.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.